TTS Pharma Limited Announces Closing of £10.3 Million Fundraising and New Board Appointment
COMPLETION OF SERIES B FUNDRAISE
TTS Pharma Limited (“TTS Pharma” or the “Company”), a UK company which is a vertically integrated supply chain manager in the cultivation, manufacturing and development of the emerging ethical cannabis market, announces that it has successfully closed a private equity investment totalling £10.3 million, on the basis of a two-tranche investment. This investment will permit TTS Pharma to become one of the leading global suppliers in this fast-growing multibillion-dollar industry, by allowing it to expand its existing supply chain, develop its own facilities and further strengthen its academic and commercial partnerships. It also enables the Company to advance its diversified operations in the wellness, nutraceutical and pharmaceutical sectors. The ethical cannabis market is set to become a high growth, disruptive and innovative new segment in the life sciences field and TTS Pharma is ideally positioned to capture rapid value within this market.
BOARD UPDATE
TTS Pharma also announces the appointment of a new Executive Chairman, Paul Atherton, who brings with him Global Institutional and Public Market experience to the board.
TTS Pharma is a unique business with core competencies and partners in drug discovery, development, separation, purification and drug delivery, incorporating the supply chain management of cannabinoids, such as CBD. It is intending to provide a transparent and accountable supply chain that produces legal and regulated cannabis-derived active agents for R&D, Bulk Active ingredients and wholesale distribution of finished goods. TTS Pharma is committed to producing the highest quality, fully compliant CBD products for use in a large range of commercial segments, alongside a number of partners, after obtaining the requisite regulatory clearance.
The pre-established supply chain including both domestic and international partners enables the Company to legally supply various CBD products to a growing range of customers. In mid-2018, TTS Pharma commenced a comprehensive R&D sponsorship programme to extract the various cannabinoids, and then to consider their chemical properties and effects, in order to develop new products in both human and animal markets.
Paul Atherton commented:
“I am delighted to join TTS Pharma as Executive Chairman. Utilising existing in-house know-how, TTS Pharma represents a unique chance to develop and produce world class, novel products for the rapidly growing new industry of ethically-based, legal cannabis products. I see a long-term opportunity to establish cost and scale advantages, allowing this Company to flourish in this attractive, global emerging industry.”
TTS Pharma CEO, Mark Tucker added:
“It is a great privilege to lead a team of highly experienced pharmaceutical professionals building an exciting portfolio of technologies and products based on world class expertise and industry leading know-how. We are well placed to build on the scientific developments driving this rapidly growing industry and provide cannabinoid products of unparalleled quality and consistency. Since my early involvement in pre-clinical cannabinoid trials in 2003, TTS Pharma has grown extensively and is now producing and developing a range of innovative and safe cannabis-based products within existing legislation and the evolving regulatory framework.”
About Paul Atherton
Paul Atherton was until the end of 2017, the Chief Executive Officer and Chief Financial Officer of Heritage Oil Limited, which held both production and exploration assets around the world. The company was one of the largest oil and gas companies listed on the Main Board of the London Stock Exchange and a member of the FTSE 250, before being taken private for US$1.6 billion in 2014. During this time Paul executed significant fundraisings, mergers and acquisitions and the eventual privatisation, generating outstanding shareholder returns. Paul is a Chartered Accountant having qualified at Deloitte and worked in corporate finance at BDO.
About TTS Pharma Ltd
TTS Pharma is a private company, incorporated in England and Wales and established in 2012, with offices in London and Liverpool. The Company has an R&D business developing products and holds deep industry expertise in extraction, separation and manufacturing of Cannabinoids. The Company has begun sales of its highly purified cannabis related products and technologies. The company abides by all legal and regulatory requirements in the UK and elsewhere and expects to gain further permissions related to these products in due course.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190522005683/en/
Contact information
Enquiries to:
TTS Pharma Ltd
Mark Tucker, CEO
mrtucker@ttspharma.com
Paul
Atherton, Chairman
patherton@ttspharma.com
Sciad
Communications Ltd
Maria Patey
TTSPharma@sciad.com
+44
203 7550571
Corporate Broker and Financial Advisor
The
Life Sciences Division Ltd
Ms Alia Minhas MBA ACSI
ali@thelifesciencesdivision.com
+44
207 8741890
Dr. Navid Malik. PhD, MSc, MBA, ACSI
navid@thelifesciencesdivision.com
+44
207 8741890
Legal Advisor
Osborne Clarke LLP
Dr
Janita Good, Partner Head of Lifescience and Healthcare
janita.good@osborneclarke.com
+44
207 1057042
M&A Advisor
ThinkingLinking
Mark
Dixon, Chief Thinking Officer
mdixon@thinkinglinking.com
+44
207 5561093
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Klarna Expands Digital Bank Offer with Peer-to-Peer Payments14.1.2026 10:00:00 EET | Press release
Klarna, the global digital bank and flexible payments provider, has launched instant peer-to-peer payments in 13 European countries, marking the next step in its evolution as a digital bank. The new feature enables Klarna customers to send money to friends and family, whether splitting bills or gifting cash, directly from the Klarna app: as simple as handing someone cash, with the protection of a regulated bank. This launch takes Klarna deeper into everyday banking, turning Klarna into a central hub for day-to-day spending and money management. It comes on the back of the Klarna Balance accounts and the rapid adoption of Klarna Card, with over 4 million sign-ups just four months after launch. Sebastian Siemiatkowski, co-founder and CEO of Klarna commented: “Customers are sick of the friction and fees of traditional banking, which is why millions signed up to Klarna Card within a few months of launch. With peer-to-peer payments we’re making it even easier to manage all of your payments
Northern Trust Secures Expanded Mandate with Swedish Pension Provider AMF Tjänstepension AB14.1.2026 10:00:00 EET | Press release
Northern Trust (Nasdaq: NTRS) today announced that it has retained and expanded its mandate with AMF Tjänstepension AB (AMF), a leading Swedish pension provider. Under the renewed agreement, Northern Trust, which has serviced AMF for more than 20 years, will continue to serve as custodian for AMF’s global pension assets and add investment operations for trade services across AMF’s total portfolio, for both pension and fund company assets. AMF is one of Sweden’s leading pension companies, managing occupational pensions for millions of individuals. With a strong focus on delivering secure and sustainable retirement outcomes, AMF combines cost efficiency with long-term investment strategies to benefit its members. Petra Sjögerås, head of Nordic Region, Northern Trust said: “As a long-standing partner to institutions in the Nordic region, Northern Trust brings extensive experience and a solutions-oriented mindset to proactively support our clients to achieve their goals now and in the futu
Notice Concerning Change of Representative Executive Officer14.1.2026 09:14:00 EET | Press release
H.U. Group Holdings, Inc. (the Company) today announced that it has resolved, at a meeting of the Board of Directors held on January 14, 2026, to change the Company’s Representative Executive Officer as described below. 1. Name and job titles of newly appointed Representative Executive Officer Name New title Current title Goki Ishikawa Representative Executive Officer, President and Group CEO Managing Executive Officer 2. Name and job titles of retiring Representative Executive Officer Name New title Current title Shigekazu Takeuchi Director and Executive Officer Director, Representative Executive Officer, Chairman, President and Group CEO 3. Reason for change In May 2025, toward realizing its Vision for 2035, the Company announced its Medium-Term Management Plan “H.U. 2030” (MMP) as well as its CEO succession plan including the timing for the selection of the next CEO. As the succession plan progressed, the Company has recognized that Mr. Goki Ishikawa is the best to lead the executio
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics14.1.2026 08:00:00 EET | Press release
Galderma (SIX: GALD) will present data on its innovative and industry-leading neuromodulator portfolio at the TOXINS 2026 International Conference in Madrid, Spain from January 14-17, 2026. The company will share data from five abstracts on two neuromodulators from its portfolio, Relfydess – the first and only ready-to-use liquid neuromodulator designed with PEARL Technology – and Dysport. Additionally, Galderma will be hosting a Relfydess Masterclass in which expert speakers will delve into the science and clinical data behind Relfydess. “At TOXINS 2026, we will demonstrate our continued leadership in neuromodulation through updates on our leading portfolio, and an educational session on Relfydess, an innovative, science-backed neuromodulator that delivers advanced performance. As the only company with a portfolio of neuromodulators, we’re building on our heritage in the space by developing next-generation solutions that address the evolving expectations of both patients and practitio
Zayed Sustainability Prize Honours Global Pioneers Advancing Progress14.1.2026 03:35:00 EET | Press release
The Zayed Sustainability Prize, the UAE’s pioneering award for innovative solutions to global challenges, today announced the cohort of 2026 winners, celebrating 18 years of empowering communities and driving inclusive, sustainable progress around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113958706/en/ The 2026 winners of the Zayed Sustainability Prize were recognised by the President of the UAE in Abu Dhabi on 13 January 2026 (Photo: AETOSWire) In a ceremony held during Abu Dhabi Sustainability Week (ADSW) and attended by Heads of State, Ministers, and business leaders, His Highness Sheikh Mohamed bin Zayed, President of the UAE, awarded the winners for their outstanding contributions to advancing sustainable development worldwide. H.H. Sheikh Mohamed bin Zayed Al Nahyan said: “The UAE remains firmly committed to supporting efforts that enhance people’s well-being and strengthen the foundations of stabili
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom